Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20321
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSeeman, Ego-
dc.contributor.authorMartin, T J-
dc.date2019-02-12-
dc.date.accessioned2019-03-04T22:04:16Z-
dc.date.available2019-03-04T22:04:16Z-
dc.date.issued2019-04-
dc.identifier.citationNature reviews. Rheumatology 2019; 15(4): 225-236-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/20321-
dc.description.abstractBone volume, microstructure and its material composition are maintained by bone remodelling, a cellular activity carried out by bone multicellular units (BMUs). BMUs are focally transient teams of osteoclasts and osteoblasts that respectively resorb a volume of old bone and then deposit an equal volume of new bone at the same location. Around the time of menopause, bone remodelling becomes unbalanced and rapid, and an increased number of BMUs deposit less bone than they resorb, resulting in bone loss, a reduction in bone volume and microstructural deterioration. Cortices become porous and thin, and trabeculae become thin, perforated and disconnected, causing bone fragility. Antiresorptive agents reduce fracture risk by reducing the rate of bone remodelling so that fewer BMUs are available to remodel bone. Bone fragility is not abolished by these drugs because existing microstructural deterioration is not reversed, unsuppressed remodelling continues producing microstructural deterioration and unremodelled bone that becomes more mineralized can become brittle. Anabolic agents reduce fracture risk by stimulating new bone formation, which partly restores bone volume and microstructure. To guide fracture prevention, this Review provides an overview of the structural basis of bone fragility, the mechanisms of remodelling and how anabolic and antiresorptive agents target remodelling defects.-
dc.language.isoeng-
dc.titleAntiresorptive and anabolic agents in the prevention and reversal of bone fragility.-
dc.typeJournal Article-
dc.identifier.journaltitleNature reviews. Rheumatology-
dc.identifier.affiliationDepartment of Medicine and St Vincent's Institute, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationMary MacKillop Institute of Health Research, Australian Catholic University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Endocrinology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1038/s41584-019-0172-3-
dc.identifier.orcid0000-0002-9692-048X-
dc.identifier.pubmedid30755735-
dc.type.austinJournal Article-
dc.type.austinReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Feb 5, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.